Literature DB >> 8014111

Biodistribution of neocarzinostatin conjugated to chimeric Fab fragments of the monoclonal antibody A7 in nude mice bearing human pancreatic cancer xenografts.

E Otsuji1, T Yamaguchi, N Yamaoka, K Taniguchi, M Kato, T Kotani, K Kitamura, T Takahashi.   

Abstract

In this study, we conjugated chimeric Fab fragments of the monoclonal antibody (MAb) A7, which reacts with pancreatic cancers, to the antitumor drug neocarzinostatin (chA7Fab-NCS) and intravenously injected 125I-labeled chA7Fab-NCS into nude mice bearing a human pancreatic cancer xenograft. We compared the tumor localization of 125I-labeled chA7Fab-NCS with that of conventional 125I-labeled A7-NCS, which was produced by conjugation of MAb A7 and NCS. 125I-Labeled chA7Fab-NCS accumulated in the tumor earlier than 125I-labeled A7-NCS, and significantly larger amounts of 125I-labeled chA7Fab-NCS had accumulated in the tumor 1 hour after injection. The results suggest that chA7Fab may be a suitable carrier for NCS in immunotargeting therapy against pancreatic cancer.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8014111      PMCID： PMC5919492          DOI： 10.1111/j.1349-7006.1994.tb02391.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


monoclonal antibody neocarzinostatin human anti‐mouse antibody fetal bovine serum N‐succinimidyl‐3‐(2‐pyridyldithio)‐propionate chimeric A7 Fab fragment‐NCS conjugate % injected dose/g standard deviation
  23 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

2.  Immune function of patients with gastrointestinal carcinoma after treatment with multiple infusions of monoclonal antibody 17.1A.

Authors:  H M Blottière; C Maurel; J Y Douillard
Journal:  Cancer Res       Date:  1987-10-01       Impact factor: 12.701

3.  Biodistribution of monoclonal antibody A7 and its F(ab')2 fragment in athymic nude mice bearing human pancreatic carcinoma.

Authors:  E Otsuji; T Yamaguchi; N Yamaoka; N Yamaguchi; J Imanishi; T Takahashi
Journal:  J Surg Oncol       Date:  1992-07       Impact factor: 3.454

4.  Specific cytotoxic effect of neocarzinostatin conjugated to monoclonal antibody A7 on human pancreatic carcinoma.

Authors:  E Otsuji; T Takahashi; T Yamaguchi; N Yamaguchi; J Imanishi
Journal:  Gastroenterol Jpn       Date:  1990-04

5.  Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients.

Authors:  M V Haspel; R P McCabe; N Pomato; N J Janesch; J V Knowlton; L C Peters; H C Hoover; M G Hanna
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

6.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

Authors:  S L Morrison; M J Johnson; L A Herzenberg; V T Oi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

7.  A monoclonal antibody against human colon cancers.

Authors:  H Kotanagi; T Takahashi; T Masuko; Y Hashimoto; K Koyama
Journal:  Tohoku J Exp Med       Date:  1986-04       Impact factor: 1.848

8.  Secretory expression of the human serum albumin gene in the yeast, Saccharomyces cerevisiae.

Authors:  K Okabayashi; Y Nakagawa; N Hayasuke; H Ohi; M Miura; Y Ishida; M Shimizu; K Murakami; K Hirabayashi; H Minamino
Journal:  J Biochem       Date:  1991-07       Impact factor: 3.387

9.  Phase I clinical trial of CO17-1A monoclonal antibody.

Authors:  A F Lobuglio; M Saleh; L Peterson; R Wheeler; R Carrano; W Huster; M B Khazaeli
Journal:  Hybridoma       Date:  1986-07

10.  Radioimmunolocalisation of bladder tumors xenotransplanted in nude mice.

Authors:  Y Hansson; S Paulie; H Ben-Aïssa; U Rudberg; A Karlsson; P Perlmann
Journal:  Anticancer Res       Date:  1988 May-Jun       Impact factor: 2.480
View more
  3 in total

1.  Distribution of neocarzinostatin conjugated to biotinylated chimeric monoclonal antibody Fab fragments after administration of avidin.

Authors:  E Otsuji; T Yamaguchi; H Matsumura; K Yamamoto; H Tsuruta; Y Yata; H Nishi; K Okamoto; K Kitamura; T Takahashi
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

2.  Decreased renal accumulation of biotinylated chimeric monoclonal antibody-neocarzinostatin conjugate after administration of avidin.

Authors:  E Otsuji; T Yamaguchi; K Yamamoto; H Matsumura; H Tsuruta; Y Yata; H Nishi; K Okamoto; K Kitamura; T Takahashi
Journal:  Jpn J Cancer Res       Date:  1997-02

3.  Effects of neocarzinostatin-chimeric Fab conjugates on the growth of human pancreatic carcinoma xenografts.

Authors:  E Otsuji; T Yamaguchi; H Tsuruta; Y Yata; H Nishi; K Okamoto; K Taniguchi; M Kato; T Kotani; K Kitamura; T Takahashi
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.